Pre-Market Earnings Report for February 6, 2026 : PM, CBOE, BIIB, AER, CG, CNC, NVT, ROIV, PAA, AN, MKTX, PIPR

Ahead of market open on 02/06/2026, multiple companies are set to report Q4 2025 results with mixed consensus EPS: Philip Morris $1.67 (+7.74%, 5 analysts), Cboe $2.93 (+39.52%, 9 analysts), Biogen $1.60 (-53.49%, 26 analysts), AerCap $3.31 (flat, 5 analysts) and Centene -$1.25 (-256.25%, 7 analysts), among others. The preview includes analyst counts, year-over-year EPS change, recent beat/miss history and cited Zacks 2025 P/E ratios for several names — detail likely to drive stock-specific reactions on the releases rather than broad market moves.

Analysis

Market structure: Earnings previews highlight clear winners in market-facing financial services and capital-markets infrastructure (CBOE, MKTX, PIPR) where consensus implies higher fee/flow capture — CBOE consensus EPS +39% YoY and MKTX resilience suggest pricing power as trading volumes and volatility remain elevated. Industrials/transportation (AER) look to benefit from secular air travel recovery; energy midstream (PAA) shows modest upside tied to oil flows. Large downside signals are concentrated in healthcare payors/biotech (CNC -256% YoY EPS swing; BIIB -53% EPS) where regulatory, reimbursement and pipeline readouts can materially move equity prices.

Risk assessment: Tail risks include adverse FDA decisions or patent/news shocks (BIIB, ROIV), tobacco regulatory or excise changes (PM), and a sudden macro slowdown that compresses fee income for CG/PIPR and trading volumes for CBOE/MKTX. Immediate (days) risk = ±5–20% post-earnings moves; short-term (weeks) risk = multiple re-rating; long-term (quarters) risk = structural demand/regulatory changes. Hidden dependencies: CG, PIPR and MKTX revenues correlate with market activity and rates; AER’s asset values hinge on residual aircraft values and capex cycles.

Trade implications: Favor long-exchange/market-structure names (CBOE, MKTX) and leasing (AER) into reports; underweight/short CNC and speculative biotech (BIIB, ROIV) unless clear pipeline beats. Use directional equity with defined stops and event-driven options for biotech (buy straddles) to capture IV spikes; harvest premium on steady beaters (sell covered calls on PM, MKTX) to improve carry. Rotate 3–6% pesos from cyclical retail/managed care into financial exchanges and select industrial leases over the next 4–12 weeks.

Contrarian angles: Consensus may underprice PM’s durable pricing power — historically consistent beats argue for income strategies rather than full exits; biotech oversold pricing may present binary asymmetric upside if trial/FDA surprises occur, so size options exposure small. AER’s deep value vs. replacement-cost aircraft cycles has precedent (post-2010 recoveries) and could outperform if travel demand remains +5–10% YoY. Beware crowded short theses in CNC/BIIB — regulatory or reinsurance tweaks can produce sharp squeezes, keep position sizing tight and use options for asymmetry.

Key Decisions for Investors

• Establish a 2–3% long position in CBOE (CBOE) ahead of earnings with a hard stop at -8% and a 4–8 week target of +15–25% if EPS/guidance confirms volume-led beat; add on any pullback >8% intraday.
• Buy 2–3% long position in MarketAxess (MKTX) on any post-earnings dip >5%; alternatively sell 1–3 month covered calls at +8–12% strikes to collect premium if the print is consistent with consensus.
• Implement event-driven option trades for BIIB and ROIV: purchase 1–2 week at-the-money straddles 1–2 days before earnings sized <=0.5% of portfolio each to capture IV; exit within 3 trading days post-release or at 50% profit / 100% loss.
• Initiate a 2% short position in Centene (CNC) if the stock rallies >5% from current levels or if Q4 guidance remains negative; set stop-loss at +12% and target a -30% move over 3–6 months, or use long-dated put spreads to limit downside risk.
• Rotate 3–6% of healthcare/consumer cyclicals into AER (long 2–3%) and PAA (long 1–2%) over the next 4–12 weeks to capture travel/energy demand normalization; take profits if AER outperforms by +20% or aircraft residual-value indicators weaken.